Cough in Idiopathic Pulmonary Fibrosis (IPF) Epidemiology Market Forecast Research 2020-2034
The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...
rheumatologyadvisor1h
Interstitial Lung Disease May Be Reliably Identified via LUS in Asymptomatic RA
Lung ultrasound (LUS) may be an effective screening tool for interstitial lung disease in patients with asymptomatic rheumatoid arthritis.
pulmonologyadvisor1h
ILD Short-Term Survival May Be Improved With Pulmonary Rehabilitation
The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...
Science Daily3h
Research pinpoints weakness in lung cancer's defenses
Scientists uncover an enzyme that boosts cancer cell metabolism to fuel growth. The enzyme, GUK1, supports metabolism in cancer cells to help tumors grow.
Too Old to Operate3h
Risk Stratification Model for Chronic Lung Disease and PH Survival
The following is a summary of “Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with ...
Healio3h
Genetic risk score plus lung function questionnaire improves COPD prediction
The ability to predict spirometry-defined COPD was significantly better when a modified lung function questionnaire score was ...
Too Old to Operate4h
Neurologic Pulmonary and Cardiac Abnormalities in Long COVID
The following is a summary of “Multidisciplinary Center Care for Long COVID Syndrome–A Retrospective Cohort Study,” published in the January 2025 issue of Pulmonology by Bailey et al. Researchers ...
clinicaltrialsarena18h
Boehringer seeks approval of lung disease drug after second Phase III success
Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.
FierceBiotech1d
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
pharmaphorum1d
Pliant slumps on decision to pause lung disease drug trial
Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 ...
manilatimes1d
Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...
thorax.bmj2d
Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...